Tumor News and Research

RSS

Researchers develop three-dimensional culture that mimics growth patterns of colon cancer stem cells

University of Pittsburgh researchers have devised a three-dimensional system in laboratory culture that mimics the growth patterns of colon cancer stem cells in patients. Their findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Study finds site of tumor impacts disease stage in head and neck cancer

Developing a molecular fingerprint for head and neck cancer tumors could help improve diagnosis and treatment for this deadly and often-times disfiguring form of cancer, according to researchers at Henry Ford Hospital in Detroit.

29 Oct 2010

New noninvasive stool DNA test to predict colorectal cancer

An investigational DNA methylation test could alter the screening landscape for colorectal cancer, according to data presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held here Oct. 27-30, 2010.

29 Oct 2010

Researchers find link between telomere length and colorectal cancer risk

For the first time, researchers have found a link between long telomeres and an increased risk for colorectal cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer Biology to Therapy, held here Oct. 27-30, 2010.

29 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Antigenics Inc. reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009.

28 Oct 2010

RExpert to discuss latest advancements in musculoskeletal bioengineering at NCKU International Symposium

The 4th International Symposium and Workshop on Virtual Interactive Musculoskeletal System, organized by National Cheng Kung University, Taiwanese Society of Biomechanics and Taiwanese Society of Biomechanics in Sports, is held on October 28th and 29th in International Conference Hall, Kuang-Fu Campus, National Cheng Kung University (NCKU), Tainan, Taiwan,

28 Oct 2010

Pancreatic cancer develops and spreads more slowly than thought before

Pancreatic cancer develops and spreads much more slowly than scientists have thought, according to new research from Johns Hopkins investigators. The finding indicates that there is a potentially broad window for diagnosis and prevention of the disease.

28 Oct 2010

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.

28 Oct 2010

Immune system may play a role in cancer therapies: Study

The immune system may play a critical role in ensuring the success of certain types of cancer therapies, according to a new study by researchers at the Stanford University School of Medicine. The research showed treatments that disable cancer-promoting genes called oncogenes are much more successful in eradicating tumors in the presence of a signaling molecule secreted by kind of immune cell called a T helper cell.

28 Oct 2010

World's largest free-standing proton therapy center opens

Hampton University, along with the Honorable Gov. Bob McDonnell and hundreds of guests, celebrated the grand opening of the Hampton University Proton Therapy Institute (HUPTI), the world's largest free-standing proton center, on Thursday.

28 Oct 2010

Scientists suggest E-cadherin can function as oncogene in some cancers

Researchers at Mayo Clinic in Florida have found that a molecule long believed to be a beneficial tumor suppressor and thus a potential cancer drug target appears to act as an oncogene in some lethal brain tumors.

28 Oct 2010

Calypso Medical initiates clinical study to evaluate tracking technology for lung tumors

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumors, today announced the initiation of the first clinical study to evaluate the use of the Calypso System for tracking lung cancer tumors during radiation delivery, including a new design of the Company's implantable Beacon transponder.

28 Oct 2010

Elevated amounts of SP2 protein turn stem cells into cancerous tumors: Research

Researchers at North Carolina State University have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. Their work may lead to new treatments for a variety of cancers.

28 Oct 2010

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

DIY breast cancer detection kit on its way

In a new discovery a “Do it Yourself” breast cancer detection device has been designed. The device will make breast cancer screening faster, cheaper and more effective. The scanning device is easy and safe to operate it could be installed in GP surgeries or even used at home.

27 Oct 2010

New guideline for using ESAs drugs in cancer patients

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.

27 Oct 2010

Reactivating three silenced molecules may provide new strategy to treat multiple myeloma

New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood.

27 Oct 2010

Pain could predict survival of liver cancer patients

Understanding the role of pain hepatocellular carcinoma (HCC) or liver cancer is critical since pain has adverse effects on quality of life and could be a predictor of survival, according to research reported in The Journal of Pain, published by the American Pain Society, www.ampainsoc.org.

27 Oct 2010

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.

27 Oct 2010